When microbes invade, they are taken up by body cells or immune cells such as monocytes, which digest them into protein fragments, or antigens, that are then presented on their cell surface. These antigens are recognized by a specialized receptor on the surface of T cells (the T cell receptor, or TCR), whose signaling prompts secretion of proteins called cytokines that coordinate the immune system's efforts to fight off the pathogen.
Each individual T cell expresses just one of myriad different versions of the TCR, each of which responds to a particular antigen. This wide diversity allows the recognition of a large repertoire of threats, but also carries the risk of inappropriate reactivity against normal tissues. While T cells that may mount such attacks are usually weeded out during their development, autoreactive cells do occasionally appear. In addition, changes to body homeostasis may sometimes provoke T cell autoimmunity. As a failsafe against these problems, a specialized type of T cell called the ''T regulatory'' cell (Treg) reins in inappropriate immune responses by secreting immunosuppressive cytokines such as IL-10. Tregs can be distinguished from other types of T cells primarily by their expression of the transcription factor FoxP3, together with a characteristic set of cell surface proteins.
The ability to restrict immune responses is delicately balanced. For example, the immune system normally tolerates several species of commensal gut bacteria, and does not mount immune responses against them. However, perturbances to the mixture of commensal bacteria communities can lead-through mechanisms that remain unclear-to bowel inflammation, and sometimes serious autoimmune diseases such as inflammatory bowel disease (IBD) or ulcerative colitis. In their paper published this month in PLOS Biology, Guillaume Sarrabayrouse, Frédé-ric Altare, Francine Jotereau, and colleagues describe a new type of T cell that mediates immune tolerance, which may be important for preventing bowel inflammation.
While examining the lymphocyte population in the lamina propria of normal human gut mucosa, Sarrabayrouse et al. noticed a group of T cells that simultaneously expressed two different types of T cellspecific surface proteins, CD4 and CD8aa. The researchers were intrigued by these double-positive CD4CD8aa lamina propria lymphocytes (DP8a LPL) because most T cells outside the thymus (where developing T cells reside)
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Previous studies had indicated that certain commensal bacteria, particularly those of the Clostridium IV group, can induce the appearance of FoxP3 regulatory T cells in mice. The authors therefore studied whether DP8a LPL responded to these commensals. In fact, although DP8a LPL expressed a widely heterogeneic population of TCRs, when presented with human monocytes pre-incubated with a Clostridium IV group bacterium, Faecalibacterium prausnitzii (F prau), a large portion of DP8a LPL responded by proliferating and secreting cytokines. Other commensals, even closely related bacteria of the Clostridium IV group, failed to elicit any response from DP8a LPL.
Occasionally, bacteria can activate T cells nonspecifically by secreting proteins called ''superantigens,'' which activate TCR signaling regardless of whether pathogen-derived antigens are being presented to the T cell. But Sarrabayrouse et al. showed that DP8a LPL proliferative and cytokine responses to F prau did not depend on superantigens, and that DP8a LPL were specifically reactive to F prauderived antigens.
Further studies showed that DP8a T cells could be detected not only in the gut but also in the peripheral blood (such cells were dubbed DP8a PBL). DP8a PBL differed from their LPL counterparts in that they lacked expression of cell surface markers associated with regulatory T cells, and a lower fraction of DP8a PBL displayed reactivity to F prau. The authors suspect DP8a PBL may be derived from DP8a LPL, although what role they play in the body remains unclear.
Sarrabayrouse et al. next investigated what happens to DP8a T cells during gut inflammation. They observed that both DP8a LPL and PBL populations were smaller in patients with active IBD than in healthy donors, which correlates with the fact that F prau levels drop precipitously during IBD flare-ups. Furthermore, the authors observed that DP8a PBL and LPL from IBD patients sometimes failed to proliferate or secrete cytokines in response to F prau. Collectively, these data suggest that DP8a T cells are a novel type of regulatory T cell that respond specifically to F prau, and whose loss or dysfunction may affect immune homeostasis in the gut. 
